Hypogammaglobulinemia and Infection Risk in an Ocrelizumab-treated Multiple Sclerosis Cohort.
Steven NobilePhilippe BeaucheminPublished in: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (2024)
Similar to ocrelizumab extension studies, our cohort demonstrated a significant rate of hypogammaglobulinemia over time, mostly with IgM. No association was found between hypogammaglobulinemia and serious infection.